PLA2G4B (phospholipase A2, group IVB (cytosolic)) Blocking Peptide (the N terminal of protein) (100ug)

This is a synthetic peptide designed for use in combination with anti-PLA2G4B antibody (Catalogue #: ARP38556_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Prices direct from Aviva Systems Biology Incorporated

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Size

100 ug

Format

Lyophilized powder

Presku

AAP38556

Target

PLA2G4B gene transcribes naturally-occurring mRNAs that are co-transcribed products of the neighboring JMJD7 and PLA2G4B genes. Incompletely processed read-through transcripts from these two loci are abundantly expressed in most tissues, but the function of the predicted protein product has not yet been determined. Alternative splicing of this gene results in different transcript variants, some of which are candidates for nonsense-mediated decay (NMD).The LOC100137047-PLA2G4B mRNAs are naturally occurring co-transcribed products of the neighboring LOC100137047 and PLA2G4B genes. Incompletely processed read-through transcripts from these two loci are abundantly expressed in most tissues, but the function of the predicted protein product has not yet been determined. Alternative splicing of this gene results in different transcript variants, some of which are candidates for nonsense-mediated decay (NMD).

Weight

114kDa

Gene Id

8681

Alternative Names

FLJ42498; HsT16992; cPLA2-beta